By inducing ICD and antigen release at the tumor site via viral oncolysis with simultaneous reprogramming of the TME, the armed virotherapy is personalized and can be combined with tumor-specific vaccines48, 49 after increasing the intratumoral infiltration of CD103+ DCs by injection of the FL cytokine. The gene discussed is ITGAE; the disease is neoplasm.